ArticleCancer medicine2020
LINC01116 accelerates nasopharyngeal carcinoma progression based on its enhancement on MYC transcription activity.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Identification and Validation of Molecular Features of the Anoikis Gene-Related Hub Genes in Nasopharyngeal Carcinoma.Applied biochemistry and biotechnology · 2025Article
- Review
- LINC01088 promotes the growth and invasion of glioma cells through regulating small nuclear ribonucleoprotein polypeptide A transcription.Bioengineered · 2022Article
- Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop.Molecular cancer · 2022Article
- LINC01116 Promotes Migration and Invasion of Oral Squamous Cell Carcinoma by Acting as a Competed Endogenous RNA in Regulation of MMP1 Expression.Computational and mathematical methods in medicine · 2022Article
- Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.International journal of biological sciences · 2022Review
- Development and validation of stemness associated LncRNA based prognostic model for lung adenocarcinoma patients.Cancer biomarkers : section A of Disease markers · 2022Article
- Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway.Thoracic cancer · 2021Article
- LINC01116 promotes the proliferation and invasion of glioma by regulating the microRNA‑744‑5p‑MDM2‑p53 axis.Molecular medicine reports · 2021Article
- Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.Journal of translational medicine · 2021Article
- Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Knocking down LINC01116 can inhibit the regulation of TGF-β through miR-774-5p axis and inhibit the occurrence and development of glioma.American journal of translational research · 2021Article
- Promising Advances in LINC01116 Related to Cancer.Frontiers in cell and developmental biology · 2021Review
- Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression.Cell death & disease · 2020Article
- LINC01116 accelerates nasopharyngeal carcinoma progression based on its enhancement on MYC transcription activity.Cancer medicine · 2020Article
- LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.OncoTargets and therapy · 2020Article
- Long non-coding RNA LINC01116 is overexpressed in lung adenocarcinoma and promotes tumor proliferation and metastasis.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs (lncRNAs) have been demonstrated to be frequently involved in the development of cancers, whereas only a few of them was investigated in nasopharyngeal carcinoma (NPC). Here, we found that LINC01116 was highly expressed in NPC cell lines, and inhibition of LINC01116 notably restrained cell viability, proliferation, and migration in NPC cells. Besides, we unveiled that LINC01116 was mainly distributed in the cytoplasm of NPC cells. Surprisingly, the cytoplasmic LINC01116 could directly interact with the 5'UTR of MYC mRNA, whereas such interaction had no influence on MYC mRNA expression, but facilitated MYC mRNA translation so as to enhance MYC protein level in NPC cells. Moreover, LINC01116 per se had no impact on the transcription of MYC targets but affected their expression through MYC-dependent manner. Furthermore, MYC overexpression offset the suppression of LINC01116 silence on NPC development. In turn, we discovered that MYC could also serve as the transcriptional activator of LINC01116 in NPC cells. By and large, our findings elucidated a LINC01116/MYC feedback loop in accelerating the tumorigenesis of NPC, revealing a promising target to establish novel biomarkers for NPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.